Neuropsychopharmacologie des addictions, Faculty of Pharmacy, University Paris Descartes, CNRS, UMR8206, and University Denis Diderot, Paris, France.
Crit Care Med. 2011 Apr;39(4):803-11. doi: 10.1097/CCM.0b013e318206d52f.
Pralidoxime is an organic cation used as an antidote in addition to atropine to treat organophosphate poisoning. Pralidoxime is rapidly eliminated by the renal route and thus has limited action. The objectives of this work were as follows. 1) Study the role of organic cation transporters in the renal secretion of pralidoxime using organic cation transporter substrates (tetraethylammonium) and knockout mice (Oct1/2⁻/⁻; Oct3⁻/⁻). 2) Assess whether sustained high plasma concentrations increase pralidoxime antidotal activity toward paraoxon-induced respiratory toxicity.
INSERM U705, Faculté de Pharmacie, Université Paris Descartes, 4 Avenue de l'Observatoire, 75006 Paris, France.
Rodents: Knockout mice (Oct1/2⁻/⁻; Oct3⁻/⁻) and Sprague-Dawley rats.
None.
In rats, the renal clearance of pralidoxime was 3.6-fold higher than the creatinine clearance. Pretreatment with tetraethylammonium (75 mg/kg) in rats or deficiencies in organic cation transporters 1 and 2 in mice (Oct1/2⁻/⁻) resulted in a significant increase in plasma pralidoxime concentrations. Lack of Oct3 did not alter plasma pralidoxime concentrations. The antidotal activity of pralidoxime (50 mg/kg intramuscularly) was longer and with greater effect, resulting in a return to normal values when administered to rats pretreated with tetraethylammonium.
Pralidoxime is secreted in rats and mice by renal Oct1 and/or Oct2 but not by Oct3. Modulation of organic cation transporter activity increased the plasma pralidoxime concentrations and the antidotal effect of pralidoxime with sustained return within the normal range of respiratory variables in paraoxon-poisoned rats. These results suggest a promising approach in an animal model toward the increase in efficiency of pralidoxime. However, further studies are needed before these results are extended to human poisoning.
派拉肟是一种有机阳离子,除了阿托品之外,还被用作治疗有机磷中毒的解毒剂。派拉肟通过肾脏途径迅速消除,因此作用有限。本研究的目的如下。1)使用有机阳离子转运体底物(四乙铵)和敲除小鼠(Oct1/2⁻/⁻;Oct3⁻/⁻)研究有机阳离子转运体在派拉肟肾分泌中的作用。2)评估持续高血浆浓度是否会增加派拉肟对氧乐果诱导的呼吸毒性的解毒作用。
法国巴黎笛卡尔大学 INSERM U705,药学院,法国巴黎 4 大道天文台,75006。
啮齿动物:敲除小鼠(Oct1/2⁻/⁻;Oct3⁻/⁻)和 Sprague-Dawley 大鼠。
无。
在大鼠中,派拉肟的肾清除率是肌酐清除率的 3.6 倍。在大鼠中用四乙铵(75mg/kg)预处理或在小鼠中缺乏有机阳离子转运体 1 和 2(Oct1/2⁻/⁻),导致血浆派拉肟浓度显著增加。缺乏 Oct3 并未改变血浆派拉肟浓度。派拉肟(50mg/kg 肌肉注射)的解毒作用更长、效果更大,当给予用四乙铵预处理的大鼠时,可恢复到正常值。
派拉肟在大鼠和小鼠中由肾脏 Oct1 和/或 Oct2 分泌,但不由 Oct3 分泌。有机阳离子转运体活性的调节增加了血浆派拉肟浓度和派拉肟的解毒作用,使氧乐果中毒大鼠的呼吸变量持续恢复正常范围。这些结果表明,在动物模型中,增加派拉肟的效率是一种有前途的方法。然而,在将这些结果扩展到人类中毒之前,还需要进一步的研究。